A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2018

Primary Completion Date

October 12, 2022

Study Completion Date

October 12, 2022

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

osimertinib

80 mg oral administration daily

Trial Locations (3)

University of Pittsburgh Medical Center, Pittsburgh

Duke University Medical Center, Durham

The Ohio State University Medical Center, Columbus